Ann: Market Update, page-2

EPAT TECHNOLOGIES MARKET UPDATE
ePAT Dementia App Validation and Implementation Studies:
ePAT Technologies has completed a pilot implementation study at Brightwater’s
Aged Care Home in Inglewood, Western Australia. The study was designed to
assess the feasibility of using ePAT to assess and monitor pain in the aged care
setting. The study conducted involved 36 residents and 18 staff, with 580 pain
assessments completed during an 8 week period. The results of the trial are now
being analysed and are due for release during February 2017.
Brightwater CEO Jennifer Lawrence says the trial has been a great opportunity to
“walk the talk” in terms of Brightwater’s commitment to innovation and the use of
technology for the benefit of clients and residents.
“If a person with dementia is in pain, sometimes the only way they may be able to
express it to our staff or family members is through agitation, so the trial has given
us another ‘tool in the toolbox’ in terms of being able to promote wellbeing and
comfort,” Ms Lawrence said.
“We know that even without words or actions people’s faces often tell us so much,
so combined with the other information collected in the app, it made perfect sense
to us to factor that into a pain assessment,” she said.
The pilot is the first of a number of implementation studies planned for 2017,
including a multicenter study involving 10 aged care homes in Victoria with a
leading aged care provider.
Brightwater was also involved in the now completed multi-centre validation study
along with Bethanie and Juniper aged care homes in which ePAT was compared to
the paper based Abbey Pain Scale. These studies were undertaken to assess
ePAT’s ability to assess pain as it was designed to do (i.e. it’s validity) and to do so
in reproducible manner (i.e. it’s reliability). These studies involved 40 residents
with moderate to severe dementia within the three residential aged care homes
in Perth, Western Australia. A total of 353 matched pair pain assessments were
undertaken. These data demonstrated a strong correlation between Abbey pain
Scale Scores and ePAT score (r = 0.88, where perfect correlation = 1.00)
demonstrating the validity of the tool. Whilst, good reliability was also
demonstrated based on a weighted Kappa scores (overall  = 0.74).

Philip Daffas, ePAT CEO commented, “The validation and implementation data sets are key requirements for CE mark and TGA approval. We have engaged with regulatory specialists in Australia and Europe and are in the process of completing the technical files and other documentation required to apply for CE mark and TGA approval as a class 1 medical device during 2017.”
ePAT Childrens’ App:
The development of the Children’s App has commenced with our technology partners nViso. A number of different facial assessment models for the children’s App have been evaluated during the past quarter and a preferred model selected for the development. In addition the recruitment of a range of children within a suitable clinical environment to build the audiovisual library and within the selected age groups (0-1 year, 1-3 years, 3-10 years and 10-12 years) has been commenced.
Summary:
We remain on track with our key milestones for both the adult Dementia App and the Children’s App. In addition we have strong supportive data and customer feedback from our clinical work to support our regulatory approach. We are on target for the initial Dementia product launch in Q3 2017 and the team is focused and working diligently to achieve all the key milestones required to achieve the end goal.
In addition, the ePAT App continues to be recognized by independent organizations. In the past week ePAT received significant publicity accompanying the launch of the CSIRO Innovation fund and Mustafa Atee, one of the ePAT inventors, was the recipient of a “disruptor” award at the Australian Computer Society awards. Mustafa’s work on developing the ePAT App was recognized as “a driver of productivity, innovation and business - able to deliver real, tangible outcomes”
About ePAT:
ePAT Technologies Limited is an Australian based company which is developing mobile medical applications that are intended to provide pain assessment for individuals that are unable to communicate verbally with their carers.
The ePAT business:
The ePAT business has evolved from research undertaken by Curtin University in Western Australia over the past 3 years. ePAT now owns the intellectual property resulting from Curtin University’s research on the ePAT Apps.
ePAT’s technology,